Deflazacort has 10 known drug interactions based on U.S. FDA drug labeling data. 10 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Carbamazepine, Clarithromycin, Diltiazem. Patients taking Deflazacort should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 10
- Major
- 10
Major (10)
- Deflazacort + Carbamazepine— Moderate CYP3A4 inducer may reduce deflazacort efficacy. Avoid concomitant use.
- Deflazacort + Clarithromycin— Strong CYP3A4 inhibitor increases 21-desDFZ exposure 3-fold; reduce EMFLAZA dose to one third of recommended dosage.
- Deflazacort + Diltiazem— Moderate or strong CYP3A4 inhibitor; reduce EMFLAZA dose to one third of recommended dosage when used concomitantly.
- Deflazacort + Efavirenz— Strong CYP3A4 inducer may reduce deflazacort efficacy. Avoid concomitant use.
- Deflazacort + Fluconazole— Moderate or strong CYP3A4 inhibitor; reduce EMFLAZA dose to one third of recommended dosage when used concomitantly.
- Deflazacort + Grapefruit Juice— Moderate or strong CYP3A4 inhibitor; reduce EMFLAZA dose to one third of recommended dosage when used concomitantly.
- Deflazacort + Pancuronium— Neuromuscular blocking agent. Concomitant use with deflazacort may increase risk of developing acute myopathy.
- Deflazacort + Phenytoin— Moderate CYP3A4 inducer may reduce deflazacort efficacy. Avoid concomitant use.
- Deflazacort + Rifampin— Strong CYP3A4 inducer significantly decreases exposure of deflazacort's active metabolite 21-desDFZ. Avoid concomitant u…
- Deflazacort + Verapamil— Moderate or strong CYP3A4 inhibitor; reduce EMFLAZA dose to one third of recommended dosage when used concomitantly.